ADH-503 protects against lipopolysaccharide induced acute lung injury

SHEN Xiaokang,XIONG Rui,LI Donghang,HE Ruyuan,LIU Bohao,LI Ning,GENG Qing

DOI: https://doi.org/10.14188/j.1671-8852.2022.0067

2023-01-01

Abstract:Objective: To study whether ADH-503 can reduce lipopolysaccharide（LPS）-induced acute lung injury（ALI） in mice and provide new ideas for clinical treatment of ALI or acute respiratory distress syndrome（ARDS）. Methods: Forty C57BL/6 male wild-type mice were selected and randomly divided into control group, LPS group（intraperitoneal injection of LPS）, ADH-503 low/high dose treatment groups, and control group（intraperitoneally injected with normal saline）. The model group were intraperitoneally injected with LPS（10 mg/kg） to induce ALI model, and the ADH-503 low/high dose treatment groups were given intraperitoneal injection of ADH-503 30 mg/kg and 60 mg/kg for 2 hours, and then intraperitoneally injected with 10 mg/kg LPS. The mice were sacrificed 12 hours after LPS perfusion, and the lung tissues were collected to detect the ratio of wet/dry weight（W/D）of lung; HE staining was used to observe the pathological damage of the lung tissue; ELISA was used to detect the TNF-α, IL-1β, and IL-6 content in lung tissue. Western Blot was aodpted to detect the expression of p-STAT3 and p-NF-κB p65 proteins in lung tissue. Results: Compared with that in control group, the lung tissue in model group showed significantly pathological changes, while the wetdry weight ratio and the content of inflammatory cytokines were significantly increased（P＜0. 05）,which means the acute lung injury models were successfully established. Compared with thaose in model group, the pathological damage scores and the levels of inflammatory factors in ADH-503 treatment group were significantly decreased（P＜0. 05）, which means ADH-503 pretreatment attenuated LPS-induced acute lung injury in mice with a concentration-dependent enhancement. While Western Blot results showed that ADH-503 pretreatment significantly inhibited the phosphorylation of STAT3and NF-κB expression induced by LPS, which means the anti-inflammatory effect of ADH-503 may be through the STAT3/NF-κB signaling pathway. Conclusion: ADH-503 can reduce the pathological changes in the lung of mice induced by LPS, thereby alleviating lung injury. ADH-503 can significantly reduce the levels of pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α. ADH-503 exerts anti-inflammatory effects, possibly through the STAT3/NF-κB signaling pathway.